Affiliation:
1. Health Technology Assessment Agency. Instituto de Salud Carlos III
2. Scientific Analysis and Prospective Group, Spanish Council for Scientific Research (Consejo Superior de Investigaciones Científicas/CSIC)
3. National Health School. Instituto de Salud Carlos III
4. Assessment Service of the Canary Islands Health Service (Servicio de Evaluación del Servicio Canario de Salud/SESCS)
Abstract
Abstract
Background
Two vaccines against rotavirus diseases, Rotarix® and RotaTeq®, are being marketed in Spain; but rotavirus is not among diseases covered by universal vaccination in Spain. The aim was to assess the efficiency of extending Spain’s current targeted rotavirus vaccination strategy including only preterm babies, to a policy of universal vaccination.
Methods
A de novo cohort-based Markov model was built to evaluate the efficiency of three rotavirus vaccination strategies in Spain, i.e., targeted, universal, and no vaccination. Using Rotarix® or RotaTeq®, we compared the cost-utility of these strategies from both a societal and Spanish National Health System (SNHS) perspective. The model represents the most important clinical events conceivably linked to rotavirus infection. Efficacy, effectiveness, safety, costs and utilities were identified by systematic reviews.
Results
Incremental cost-utility threshold (ICUR) is €23,638/QALY (Quality Adjusted Life Year) for targeted vaccination with Rotarix®. The ICUR for the rest of the strategies evaluated are above €30,000/QALY. Sensitivity analysis shows the price as the only parameter that could make the universal vaccination strategy efficient.
Conclusions
Considering a threshold of €25,000/QALY, only targeted vaccination with Rotarix® from the societal perspective would be efficient. Price drops of 36.9% for Rotarix® and 44.6% for RotaTeq® would make universal vaccination efficient.
Publisher
Research Square Platform LLC
Reference29 articles.
1. 1. World Health Organization,. Rotavirus [Internet]. 2022 [citado 22 de noviembre de 2022]. Disponible en: https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/vaccines-quality/rotavirus
2. 2. European Centre for Disease Prevention and Control. ECDC Expert opinion on rotavirus vaccination in infancy. ECDC; 2017.
3. 3. Poelaert D, Pereira P, Gardner R, Standaert B, Benninghoff B. A review of recommendations for rotavirus vaccination in Europe: Arguments for change. Vaccine. 2018;36(17):2243-53.
4. 4. Bruijning-Verhagen P, van Dongen JAP, Verberk JDM, Pijnacker R, van Gaalen RD, Klinkenberg D, et al. Updated cost-effectiveness and risk-benefit analysis of two infant rotavirus vaccination strategies in a high-income, low-endemic setting. BMC Med. 2018;16(1):1–15.
5. 5. Hansen Edwards C, De Blasio BF, Salamanca BV, Flem E. Re–evaluation of the cost–effectiveness and effects of childhood rotavirus vaccination in Norway. PLoS ONE. 2017;12(8):1–19.